BAY-X 1005

Name	(2R)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetic acid
Synonyms	DG 031 BAY 1005 Velifapon VELIFLAPON BAY-X 1005 2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid (αR)-α-Cyclopentyl-4-(2-quinolinylmethoxy)-benzeneacetic acid (2R)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetic acid
CAS	128253-31-6

Molecular Formula	C23H23NO3
Molar Mass	361.43
Density	1.242±0.06 g/cm3(Predicted)
Melting Point	169-171 °C
Boling Point	555.4±40.0 °C(Predicted)
Solubility	DMSO: soluble5mg/mL (clear solution)
Appearance	powder
Color	white to beige
pKa	4.47±0.10(Predicted)
Storage Condition	2-8°C
In vitro study	Veliflapon (BAY X 1005; DG-031) effectively inhibits the synthesis of LTB4 in A23187-stimulated leukocytes from rats, mice and humans (IC 50 s of 0.026, 0.039 and 0.22 μM, respectively) as well as the formation of LTC4 (IC 50 of 0.021 μM) in mouse peritoneal macrophages stimulated with opsonized zymosan.

biological activity	velifapon (BAY X 1005; DG-031), selective 5-lipoxygenase activating protein (FLAP) inhibitors. Velilapon is also an inhibitor of leukotriene B4 and C4 synthesis.
Animal Model:	Female apoE/LDLR-DKO mouse model
Dosage:	18.8 mg/kg
Administration:	Diet; per day during 16 weeks
Result:	Inhibited atherogenesis.

Last Update：2024-04-09 21:49:45